 HAUPPAUGE, N.Y., Dec. 02, 2020 GLOBE NEWSWIRE -- Chembio Diagnostics, Inc. Nasdaq: CEMI a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority BARDA, which is part of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The contract will support the development and pursuit of U.S. Food and Drug Administration FDA Emergency Use Authorization EUA for a rapid, multiplex DPP Respiratory Antigen Panel point-of-care test system using Chembios proprietary DPP technology for the upcoming flu season. 